

<p style="text-align: center;"><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Form PTO-1449 (Modified) (Use several sheets if necessary)</p> <p style="text-align: center;">OPIE IAPR SEP 20 2006 PATENT &amp; TRADEMARK OFFICE</p>				<b>COMPLETE IF KNOWN</b>	
				Application Number	10/723,354
				Confirmation Number	8250
				Filing Date	November 25, 2003
				First Named Inventor	Patrick L. Iversen
				Group Art Unit	1633
				Examiner Name	Epps-Ford, Janet L.
Attorney Docket No. 50450-8311.US03					
Sheet 1 of 3					

<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initials*	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		NUMBER	Kind Code (if known)				
JE	A1	5,585,479		Hoke et al.	12/96		
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initials*	Cite No.	Foreign Patent or Application			Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office	NUMBER	Kind Code (if known)			
JE	A2	PCT	WO 00/20432	WO	4/00		
JE	A3	PCT	WO 00/24885	WO	5/00		
JE	A4	PCT	WO 00/74667	WO	12/00		
<b>OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS</b>							
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.					T
JE	A5	Arora V. et al., <i>Current Opinion in Molecular Therapeutics</i> , 3(3):249-257 (2001).					
JE	A6	Bolz, et al., <i>The FASEB Journal</i> , 14:255-260 (2000).					
JE	A7	Branch, A.D., "A good antisense molecule is hard to find", <i>TIBS</i> 23:45-50 (1998).					
JE	A8	Branch, A.D., "A good antisense molecule is hard to find", <i>TIBS</i> , 47-48 (1998).					
JE	A9	Bristow, J., et al., "Antisense RNA regulation by transcripts from the human F450c21B gene and P450c21A "pseudogene" <i>Clinical Research</i> , 41(2):272A abstract only (1993).					
JE	A10	Cai, Y., et al., "Inhibition of metabolism of benzo[a]pyrene by a c-5 propyne antisense oligonucleotide against cytochrome P450 1A1 in mouse hepatoma cell line (Hepa-1)" SOT Annual Meeting pp. 21 abstract # 101 (1998).					
JE	A11	Chirila et al., <i>Biomaterials</i> , 23:321-342 (2002).					

EXAMINER	DATE CONSIDERED
/Janet Epps Ford/	10/19/2006
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Form PTO-1449 (Modified) (Use several sheets if necessary)				<b>COMPLETE IF KNOWN</b>	
				Application Number	10/723,354
				Confirmation Number	8250
				Filing Date	November 25, 2003
				First Named Inventor	Patrick L. Iversen
				Group Art Unit	1633
				Examiner Name	Epps-Ford, Janet L.
Sheet	2	of	3	Attorney Docket No.	50450-8311.US03

<b>FOREIGN PATENT DOCUMENTS</b>						
Examiner Initials*	Cite No.	Foreign Patent or Application		Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office	NUMBER			
JE	A12	Correia, M.A. and Castagnoli, Jr., N., "Pharmacokinetics: Drug Biotransformation" Basic and Clinical Pharmacology Katzung (ed.) Appleton & Lange, Los Altos, CA, pp. 36-37 (1987).				
JE	A13	Dejardines, J., et al., "Cholesteryl-Conjugated Phoshorothioate Oligodeoxynucleotides Modulate CYP2B1 Expression In Vivo" <i>J. of Drug Targeting</i> , 2:477-485 (1995).				
JE	A14	DeLong, R.K., et al., "Comparative Pharmacokinetics, Tissue Distribution, and Tumor Accumulation of Phosphorothioate, Phosphorodithioate, and Methylphosphonate Oligonucleotides in Nude Mice", <i>Antisense &amp; Nucleic Acid Drug Development</i> , 7:71-77 (1997).				
JE	A15	Desjardines, J.P. and Iversen, P.L., "Inhibition of the Rat Cytochrome P450 3A2 by an Antisense Phosphorothioate Oligodeoxynucleotide In Vivo" <i>J. of Pharmacology and Experimental Therapeutics</i> , 275(3):1608-1613 (1995).				
JE	A16	Einolf, H.J. and Baird, W.M., "Effects of antisense oligonucleotides on the metabolism of benzo(a)pyrene by P4501A1 in the mouse hepatoma cell line, Hepa-1" <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> 35:134 abstract # 801 (1994).				
JE	A17	Gewirtz, A.M., et al., "Facilitating oligonucleotide delivery: Helping antisense deliver on its promise", <i>Proc Natl Acad Sci USA</i> , 93:3161-3163 (1996).				
JE	A18	Hanecak, R., et al., "Antisense Oligonucleotide Inhibition of Hepatitis C Virus Gene Expression in Transformed Hepatocytes", <i>Journal of Virology</i> , 70(8):5203-5212 (1996).				
JE	A19	Hangeland, J.J., et al., "Tissue Distribution and Metabolism of the [.sup.32 P]-Labeled Oligodeoxynucleoside Methylphosphonate-Neoglycopeptide Conjugate, [YEE(ah-GalNAc).sub.3 ]-SMCC-AET-pU.sup.m pT.sub.7, in the Mouse", <i>Antisense &amp; Nucleic Acid Drug Development</i> , 7:141-149 (1997).				

EXAMINER <i>/Janet Epps Ford/</i>	DATE CONSIDERED <i>10/19/2006</i>
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Form PTO-1449 (Modified) (Use several sheets if necessary)				<b>COMPLETE IF KNOWN</b>	
				Application Number	10/723,354
				Confirmation Number	8250
				Filing Date	November 25, 2003
				First Named Inventor	Patrick L. Iversen
				Group Art Unit	1633
				Examiner Name	Epps-Ford, Janet L.
Sheet	3	of	3	Attorney Docket No.	50450-8311.US03

<b>FOREIGN PATENT DOCUMENTS</b>									
Examiner Initials*	Cite No.	Foreign Patent or Application		Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
		Office	NUMBER						
JE	A20	<i>Hudziak et al., Antisense &amp; Nucleic Acid Drug Development, 10:163-176 (2000).</i>							
JE	A21	<i>Ingelman-Sundberg, Journal of Internal Medicine, 250:186-200 (2001).</i>							
JE	A22	<i>Nelson, D.R., et al., "The P450 Superfamily: Update on New Sequences, Gene Mapping, Accession Numbers, Early Trivial Names of Enzymes, and Nomenclature", DNA and Cell Biology, 12(1):1-51 (1993).</i>							
JE	A23	<i>Rait et al., Cancer Gene Therapy, 8(10):728-739 (2001).</i>							
JE	A24	<i>Rojanasakul, Y., "Antisense oligonucleotide therapeutics: drug delivery and targeting", Advanced Drug Delivery Reviews, 18:115-131 (1996).</i>							
JE	A25	<i>Sindhu, R.K., et al., "Inhibition of Cytochrome P450 1A1 by Antisense Phosphorothioate Oligonucleotide in Hepa Iclc7 Cells", Biochemical and Biophysical Research Communications, 229:673-680 (1996).</i>							
JE	A26	<i>Stanley T. Crooke, Basic Principles of Antisense Therapeutics, Springer-Verlag, NY, p. 3 (1998).</i>							
JE	A27	<i>Stein et al., Pharmacology &amp; Therapeutics, 85:231-236 (2000).</i>							
JE	A28	<i>Summerton et al., Antisense &amp; Nucleic Acid Drug Development, 7:187-195 (1997).</i>							

EXAMINER  <i>/Janet Epps Ford/</i>	DATE CONSIDERED  <i>10/19/2006</i>
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).	